• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Karyopharm - oncology





























That’s the point. You all failed. It’s time to wind down the staff. Of the two of us, it’s probably more important for you to figure out where you fall out in that than it is me.
 




















Another week another round of firings
Richard fiddles while Karyo burns
When will senior leaders be held accountable
When only the cronies and incompetent are left


SC will leave I the next year or so for a CEO job, and then talk crap about how bad of a drug Selli is, how it’s impossible to sell blah blah blah, until then she’ll act like the reason this dog drug doesn’t sell is because of the terrible sales force we have.

It’s a bad drug, seldom used, toxic with marginal efficacy. Some drugs get approved that just aren’t that good. It happens. We have one. We are doing what we can but after four years, the uptake is still minimal…for a reason. It’s the drug…not the sales team.
 








Who was fired?


Well...the company would probably say no one got fired...there were dissolutions of positions or resignations. Don't believe either. All SC wants is a bunch of Amgen losers who have been beaten into submission and will not/cannot think on their own. This place is a mess...I guess it always has been. Just now clowns running he circus.
 




Well...the company would probably say no one got fired...there were dissolutions of positions or resignations. Don't believe either. All SC wants is a bunch of Amgen losers who have been beaten into submission and will not/cannot think on their own. This place is a mess...I guess it always has been. Just now clowns running he circus.